ROTTERDAM, The Netherlands, July 6, 2011 /PRNewswire/ --
Skyline Diagnostics B.V. (Skyline), a biotechnology company focusing on development and marketing of gene signature-based diagnostic assays based in The Netherlands, today announced that it has signed a Research Agreement with Johnson & Johnson Pharmaceutical Research and Development division of Janssen Pharmaceutica N.V. (Janssen). Under the agreement Skyline, using its proprietary knowledge and technologies in the area of genetic profiling and bioinformatics will work with Janssen to generate and analyze diagnostic information related to the use of an undisclosed, marketed compound. Under the terms of the agreement, Skyline will receive R&D funding and could receive payments on the achievement of certain research milestones. Financial details of the agreement were not disclosed.
“We are very pleased with extension of this exciting companion diagnostic program,” said Henk Viëtor, CEO of Skyline Diagnostics, “this collaboration will provide both companies the opportunity to develop a unique personalized medicine approach to help identify patients at increased risk of side effects.”
AboutSkyline Diagnostics BV
Skyline Diagnostic with its headquarters in Rotterdam, The Netherlands, develops and markets array-based diagnostic tests using gene signatures for personalized medicine. The company has successfully translated several important scientific discoveries into diagnostics. These products, called Profilers, are based on gene expression and offer a high additional clinical value. Skyline Diagnostics’ Profilers will provide the clinician in-depth insight in the prognosis of individual patients and facilitate the treatment decision making process. The company has built strong collaborations with leading scientists and has strategic alliances with industrial partners for distribution and manufacturing, including a ‘Powered by Affymetrix’ partnership.
Website: http://www.skyline-diagnostics.com
SOURCE Skyline Diagnostics B.V.
